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Worldwide, sickle cell disease (SCD) is the most common hemoglobinopathy among which SS pattern is more common [1]. Sickle cell anemia has the 
highest predicted frequencies of up to 10% spanned in Central 
India and India ranked the second-worst affected country in terms 
of predicted sickle cell anemia births [2]. In December 2017, 
the Food and Drug Administration approved hydroxyurea (HU) 
in pediatric sickle cell anemia from 2 years of age in recurrent 
moderate-to-severe painful crises [3].
Few observational studies in children suggested that HU was 
safe and beneficial [4-6]. Among the short-term side effects of HU, 
hematological toxicity was reported in a majority of studies, which 
include cytopenia and/or significant decrease in total white blood 
cell, platelet, and absolute reticulocyte counts (ARC) which are dose 
dependent, requiring dose reduction or temporary discontinuation 
of HU. Furthermore, a transient increase in transaminase activity, 
serum creatinine, skin rash, nausea, hair loss, diarrhea, idiopathic 
thrombocytopenic purpura, and renal failure in systemic lupus 
erythematous syndrome has been reported [7].
The present study evaluated the various toxicities/adverse 
drug events and beneficial effects by clinical, hematological, and 
biochemical parameters in children with SCD treated with HU 
therapy.
MATERIALS AND METHODS
This study was a prospective longitudinal follow-up study 
conducted over a period of 2 years. After obtaining clearance 
from the Institutional Ethical Committee and informed consent 
from parents or guardians, 40 children of severe SCD (SS pattern) 
of either sex between 5 and 15 years of age attending sickle 
cell clinic/pediatric outpatient department were enrolled. The 
indications to start HU therapy were two or more acute painful 
events per year requiring hospitalization, frequent blood 
transfusions (>3/year), one episode of previous acute chest 
syndrome, at least one episode of cerebrovascular event, and at 
least one episode of avascular necrosis of femur. The exclusion 
criteria were SCD children <5 years age, other systemic illness, 
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regularly on drugs such as theophylline, estrogen or calcium 
channel blockers, deranged hematological/renal/hepatic 
laboratory parameters, and parents not willing for participation.
Considering the expected toxicity thrombocytopenia which 
was 8.3% (Kinney et al. [4]) precision 10%, desired confidence 
level (1−α) 95%, minimum sample size required was 30 with 10% 
lost to follow up. Total sample size required was 33. However, 40 
subjects were enrolled.
Required sample size (n):
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At enrollment, a detailed history of previous symptoms, 
hospitalizations, blood transfusion rate, frequency of 
vaso-occlusive crises, acute painful events, acute chest syndrome, 
avascular necrosis of femur, and stroke was elicited. The same 
was noted on follow-up visits. The laboratory parameters 
assessed at baseline and follow-up visits were hemoglobin 
(Hb), absolute neutrophil count (ANC), ARC, platelet count 
(Plt. C), hemoglobin F (HbF) level and serum glutamic-pyruvic 
transaminase (SGPT)/alanine aminotransferase (ALT), and 
serum creatinine level. Enrolled cases were treated with HU in a 
fixed dose of 10 mg/kg once daily. During the follow-up visits, 
cases were evaluated for compliance of HU, its toxic effects, 
adverse events from histories, and clinical examination. HbF 
levels were estimated after the completion of 2 years of HU 
therapy.
Hematological toxicity was defined as one or more of the 
following: (i) Hb – 20% decrease from entry/previous value or 
Hb <4.5 g/dl, (ii) ANC <2.0 × 103/mm3, (iii) ARC <80 × 103/mm3 
unless Hb was 9.0 g/dl or higher, and (iv) Plt. C <80 × 103/mm3. 
Biochemical toxicity was defined as Hepatic toxicity ALT/SGPT 
>twice the upper limit of baseline renal toxicity serum creatinine 
>1.0 mg/dl. Any toxicity or minor adverse drug events were 
managed as per the standard protocols [4]. HU when withheld 
for mean duration of 2 weeks period and restarted at the same 
dose after normalization of the deranged laboratory parameters. 
Statistical software STATA version 10.0 was used for statistical 
analysis.
RESULTS
In this study, most children belonged to 12–15 years (55%), 
9–11 years (22.5%), and 5–8 years (22.5%) age groups. There 
were 22 (55%) males and 18 (45%) females belonging to Mahar, 
Teli, Kunbi, Muslim, and Gond community. Indications to start 
Hydroxyurea were the acute painful events ≥2/year requiring 
hospitalization (52.5%), frequent blood transfusions ≥3/year 
(27.55%), stroke (15%), acute chest syndrome (2.5%), and 
avascular necrosis of femur (2.5%). Out of 40 cases, 36 (90%) 
cases had completed regular monthly follow-up for 2 years while 
4 (10%) cases were lost to follow up. Further, statistical analysis 
was performed on 36 cases only.
During hydroxyurea therapy, clinical events and toxicities 
were noted as shown in Table 1. The clinical adverse drug events 
observed in our study were nausea in 3 cases (8.33%), diarrhea in 
1 (2.78%), and hematuria in 1 case (2.78%).
As shown in Table 2, the mean acute painful events and blood 
transfusions rates reduced significantly at the end of 2 years of 
HU therapy (p=0.001). No recurrence of acute chest syndrome 
or occurrence of stroke event was seen. The mean Hb and mean 
HbF level increased significantly after HU therapy. The reduction 
Table 1: Clinical events and toxicities observed during hydroxyurea therapy
Clinical events and toxicities Follow-up visits Total events Cases (%)
1st 2nd 3rd 4th 5th 6th 7th 8th
Acute painful events 11 13 0 10 0 5 1 3 43 30 (83.33)
Acute chest syndrome 0 0 0 0 0 0 0 0 0 0
Stroke 1 2 0 0 0 0 0 0 3 2 (5.56)
Avascular necrosis of femur 0 1 0 0 1 0 0 0 2 1 (2.78)
Splenic sequestration crises 3 2 1 2 0 4 2 0 14 6 (16.7)
Hemolytic crises 4 6 0 2 2 1 2 0 17 11 (30.6)
Aplastic crisis 0 0 1 0 0 0 0 0 1 1 (2.78)
Acute febrile illness 0 1 1 0 1 1 0 0 4 3 (8.33)
Pneumonia 0 0 0 1 0 0 0 0 1 1 (2.78)
Osteomyelitis 0 0 0 0 1 0 0 0 1 1 (2.78)
Cholelithiasis 0 0 0 0 1 1 0 0 2 2 (5.56)
Toxicities
Anemia 1 1 1 2 0 1 1 0 7 5 (13.89)
Neutropenia 0 2 1 0 0 0 0 0 3 3 (8.33)
Reticulocytopenia 0 0 0 0 0 0 0 0 0 0 (0)
Thrombocytopenia 2 1 1 1 0 1 1 0 7 4 (11.11)
Renal toxicity 2 0 0 0 0 2 0 0 4 4 (11.11)
Hepatic toxicity 1 1 0 1 0 0 0 0 3 3 (8.33)
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in mean acute painful events statistically correlated with rising 
mean HbF level after HU therapy (correlation coefficient=0.3954, 
p=0.0170), as shown in Fig. 1.
DISCUSSION
Many studies demonstrated a beneficial effect of HU in SCD 
children [4-6]. Our study included 5–15-year-old SCD patients 
with severe painful crisis (>3 vaso-occlusive events/year) similar 
to the studies done by Kinney et al. [4], Scot et al. [6], and Ferster 
et al. [8]. In the present study, HU was given in a single fixed dose 
of 10 mg/kg/day orally without escalation due to fear of toxicity in 
pediatric age group. Similarly, Italia et al. [9] used HU 10 mg/kg/d 
and increased it up to 15 mg/kg/d. Lima et al. [10] used HU in 
an escalation dose of 10–20 mg/kg/d. Patel et al. [11]undertook 
study with minimal dose of HU (10 mg/kg/d) in pediatric and 
adult SCD patients.
Kinney et al. [4] in HUG-KIDS study used initial single oral 
dose of 15 mg/kg/d, which were increased by 5 mg/kg/d, if no 
toxicity was seen and the mean dose was 26.6±6.2 mg/kg/d. 
Tshilolo et al. [12] demonstrated safety and beneficial effects 
of HU in sickle cell anemia children in sub-Saharan Africa in 
a mean dose of 17±1.8 mg/kg/d. Opoka et al. compared HU 
(20±2.5 mg/kg/d) to placebo for 12 months and concluded that 
HU was safe for SCD children of sub-Saharan Africa, without 
increased severe malaria, infections, or adverse events [13].
In our study, transient clinical adverse drug events were nausea 
(8.33%), diarrhea (2.78%), and hematuria (2.78%). Kinney 
et al. [4] also observed similar adverse clinical events. Jayabose 
et al. [14] also reported nausea in their study of HU in sickle 
cell anemia. In the present study, anemia was the most common 
transient hematological toxicity followed by thrombocytopenia 
and neutropenia. However, reticulocytopenia was not observed. 
Hematological toxicity was common and transient in nature as 
reported in many previous studies [4-6,14-17]. Kinney et al. [4] 
reported various cytopenias, namely, anemia, reticulocytopenia, 
neutropenia, and thrombocytopenia from HU. Thrombocytopenia 
was reported in the studies by other authors also [8,16-18].
Renal toxicity occurred in four and hepatic toxicity in three 
cases in our study. All these toxicities were transient requiring 
temporary discontinuation of HU. Hepatotoxicity was also 
reported in studies done by Kinney et al. [4] and Wang et al. [18]. 
Renal toxicity was not reported in most of the studies. Odievre 
et al. [7] mentioned that a 13-year-old girl developed acute renal 
failure when systemic lupus erythematous syndrome occurred and 
required hemodialysis and definitive cessation of HU treatment. 
PED-HUG study by Kinney et al. [4] showed that the effects of 
HU on kidney and liver functions were negligible during the study. 
All our cases were alive and no case of malignancy/leukemia or 
sustained myelosuppression was observed.
In our study, we found a significant reduction in the number 
of acute painful events/year/person and mean blood transfusions 
rate after HU therapy and similar observations were made in 
the previous studies also [4,6,8-11,16,19,20]. We also found a 
significant increase in HbF at the end of 2 years of HU therapy and 
the rise significantly correlated with the reduction of the painful 
events. Ferster et al. [15] showed that mean HbF in SCD pediatric 
patients on HU therapy raised from 4.7% to 15%. Similar rise in 
HbF was observed by other authors also [4,9-11,21].
Figure 1: Correlation of acute painful events with hemoglobin F level 
on hydroxyurea therapy
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Table 2: Comparison of sickle cell disease-related clinical events and laboratory parameters before and after hydroxyurea therapy (n=36)
Clinical events and laboratory parameters Before therapy After 2 years p value
Mean SD Mean SD
Clinical events (per year per person)
Acute painful events 2.11 0.94 0.25 0.5 0.001
Blood transfusion rate 1.88 1.36 0.30 0.57 0.001
Acute chest syndrome 0.027 0.16 0.027 0.16 1.00
Strokes 1.66 0.37 0 - -
Avascular necrosis of femur 0.027 1.66 1.66 0.37 1.00
Laboratory parameters
Hemoglobin (g/dl) 9.14 1.19 9.27 1.26 0.0012
Absolute neutrophil count (×103/mm3) 4.22 1.56 4.05 1.60 0.5581
Absolute reticulocyte count (×103/mm3) 163.52 78.48 144.42 64.02 0.2821
Platelet count (×103/mm3) 258.80 81.39 262.21 94.76 0.8523
Serum glutamic-pyruvic transaminase/alanine aminotransferase (IU/L) 22.75 6.56 22.27 6.38 0.7353
Serum creatinine (mg/dl) 0.64 0.12 0.57 0.20 0.0728
Hemoglobin F (%) 17.80 5.73 18.13 5.79 0.001
Somkuwar et al. Hydroxyurea therapy in children with sickle cell disease
Vol 7 | Issue 1 | January 2020 Indian J Child Health 32
The study had few limitations. The study involved only 
40 cases and it was of short duration. Further studies incorporating 
larger sample size and long-term duration are needed to assess 
sustained efficacy, safety, and toxicity of HU therapy in SCD 
children.
CONCLUSION
HU is safe and effective in treating the children with SCD on a 
short-term basis in a fixed low dose of 10 mg/kg/day.
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